Noteworthily, we identified a KLF14 activator, fluphenazine, which markedly reduces the cellular labile iron pool (LIP) content and suppresses the growth of HCC cells in vitro and in vivo. The gene discussed is KLF14; the disease is hepatocellular carcinoma.